公司介绍：
About Novo Nordisk
Novo Nordisk is one of the world’s leading bio-pharmaceutical companies and the world leader in insulin production for diabetes treatment. With headquarters in Copenhagen, Denmark, Novo Nordisk employs approximately 18,000 people in more than 70 countries and markets its products in 179 countries. There are also production plants in occident.
Novo Nordisk has a long history since 1923. For over 80 years, Novo Nordisk continues to adopt advanced biotechnology to improve the research and means of production for insulin. It is a major force in insulin manufacture and diabetes treatment. The company was the first to introduce longer acting insulin (NPH and Lente insulin), pre--mixed insulin, highly purified insulin (MC and RI insulin), human insulin and insulin pens, which tremendously improved the level of diabetes treatment and control, and life quality of people with diabetes. In addition, Novo Nordisk is in a leading position within the areas of coagulation disorders, growth disorders and hormone replacement therapy.
As early as 1960s, Novo Nordisk's products have been introduced to the China market. In 1994, Novo Nordisk board decided to land a strategic investment project in China. Novo Nordisk (Tianjin) Biotechnology Co., Ltd. was then set up in China. The company's headquarters and Biotechnology R
|
|
